Monopar Therapeutics MNPR Institutional Ownership

Updated Oct 10, 2026

Monopar Therapeutics (NASDAQ:MNPR) was reported as a holding by 97 institutional investors in 13F filings for the quarter ended June 30, 2026.

• These investors held 72.84% of Monopar Therapeutics' outstanding shares at the end of Q2 2026, down from 93.08% in Q1 2026.
• Total shares held in Monopar Therapeutics fell 0.21% from Q1 2026, while the number of holders rose 136.59% from Q2 2025.
• Of the 97 holders, 64 added to their positions, 24 reduced their stakes and 9 left their positions unchanged in Q2 2026.
• Combined, institutional investors held 6.22Mn shares of MNPR as of Q2 2026, down 13.15K from the prior quarter and up 3.06Mn from a year earlier.
• Jupiter Topco LLC held the largest position in MNPR at 1.31Mn shares as of June 30, 2026, or 15.36% of shares outstanding.
• The biggest increases in MNPR positions during Q2 2026 came from TCG Crossover Management, LLC (+71.22K shares), Driehaus Capital Management LLC (+50.88K shares), BlackRock, Inc. (+32.25K shares), Neuberger Berman Group LLC (+12.76K shares) and Geode Capital Management, LLC (+12.66K shares).
• On the other side, among holders that kept a position in Monopar Therapeutics, the largest reductions in Q2 2026 came from Adage Capital Partners GP, L.L.C. (-100K shares), Bank of America Corp (-56.45K shares), ADAR1 Capital Management, LLC (-46.68K shares), T. Rowe Price Associates Inc (-44K shares) and Saturn V Capital Management LP (-33.65K shares).
• According to Business Quant data, the leading holders of MNPR for Q2 2026 were Jupiter Topco LLC (1.31Mn shares), Ra Capital Management, L.P. (667.21K shares), BlackRock, Inc. (348.82K shares), Deerfield Management Company, L.P. (323.75K shares), Saturn V Capital Management LP (311.98K shares), Siren, L.L.C. (270.12K shares), ADAR1 Capital Management, LLC (217.59K shares), Polar Capital Holdings PLC (214.47K shares), Vanguard Capital Management LLC (209.71K shares) and Adage Capital Partners GP, L.L.C. (209.19K shares).